Life Saving Drugs Program – Asfotase alfa (Strensiq®)


Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement – 13 May 2022

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date: 
13 May 2022
Publication type: 
Intended audience: 
General public

This document summarises the Life Saving Drugs Program Expert Panel's consideration of the application from Alexion Pharmaceuticals Australasia Pty Ltd to include asfotase alfa (Strensiq®) on the Life Saving Drugs Program for the treatment of perinatal- and infantile-onset hypophosphatasia (HPP).

The document contains:

  • Overview
  • Background
  • PBAC Consideration
  • Consumer Input
  • LSDP Expert Panel Consideration
    • Funding Criteria
    • Pricing Issues
  • Treatment Guidelines
    • Management of Uncertainties
  • Context
  • Sponsor’s Comment